scholarly journals Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review

2020 ◽  
Vol 16 (1) ◽  
pp. 36-47
Author(s):  
Romeo-Gabriel Mihăilă

Background: Dyslipidemia is the main factor involved in the occurrence and progression of coronary artery disease. Objective: The research strategy is aimed at analyzing new data on the pathophysiology of dyslipidemia involvement in coronary artery disease, the modalities of atherogenic risk estimation and therapeutic advances. Method: Scientific articles published in PubMed from January 2017 to February 2018 were searched using the terms "dyslipidemia" and "ischemic heart disease". Results: PCSK9 contributes to the increase in serum levels of low-density lipoprotein-cholesterol and lipoprotein (a). The inflammation is involved in the progression of hyperlipidemia and atherosclerosis. Hypercholesterolemia changes the global cardiac gene expression profile and is thus involved in the increase of oxidative stress, mitochondrial dysfunction, and apoptosis initiated by inflammation. Coronary artery calcifications may estimate the risk of coronary events. The cardioankle vascular index evaluates the arterial stiffness and correlates with subclinical coronary atherosclerosis. The carotid plaque score is superior to carotid intima-media thickness for risk stratification in patients with familial hypercholesterolemia and both can independently predict coronary artery disease. The lipoprotein (a) and familial hypercholesterolemia have a synergistic role in predicting the risk of early onset and severity of coronary atherosclerosis. A decrease in atherosclerotic coronary plaque progression can be achieved in patients with plasma LDL-cholesterol levels below 70 mg/dL. A highly durable RNA interference therapeutic inhibitor of PCSK9 synthesis could be a future solution. Conclusion: The prophylaxis and treatment of coronary artery disease in a dyslipidemic patient should be based on a careful assessment of cardio-vascular risk factors and individual metabolic particularities, so it may be personalized.

Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
Pao-Hsien Chu

Background and aims: Elevated lipoprotein(a) is an independent risk factor for atherosclerotic cardiovascular disease especially in familial hypercholesterolemia. The association of elevated lipoprotein(a) within non-familial hypercholesterolemia or healthy population however, is not known. Therefore, we investigated the associations between elevated lipoprotein(a) and the risk of cardiovascular disease in a non-familial hypercholesterolemia clinically healthy young age cohort. Methods: In this retrospective cohort study, we reviewed medical records of 3,427 participants with lipoprotein(a) levels from a tertiary healthcare center in Taiwan. We further classified lipoprotein(a) level into four groups and analyzed cardiovascular events. Results: Our study population had a mean age 46 years old that were 78% male. Mean total cholesterol and low-density lipoprotein level were 195 mg/dL and 118 mg/dL respectively. Overall, 12.9% of the participants had an elevated lipoprotein(a) level (>30 mg/dL), and 2.7% had a very high level (>70 mg/dL). Thirty-three events including 6 participants with stroke and 27 with coronary artery disease were identified. A lipoprotein(a) level >70 mg/dL was associated with a higher risk of coronary artery disease events in Kaplan-Meier analysis. Aging was associated with a higher lipoprotein(a) value in the male participants but not in the female participants. However, the severity of fatty liver was not positively associated with lipoprotein(a) value. Conclusions: Elevated lipoprotein(a) was associated with coronary events but not the severity of fatty liver disease in non-familial hypercholesterolemia clinically healthy population. Aging may be associated with a higher lipoprotein(a) level in males but not females.


Open Medicine ◽  
2011 ◽  
Vol 6 (1) ◽  
pp. 107-112
Author(s):  
Setareh Davoudi ◽  
Abbas Omran ◽  
Mohammad Boroumand ◽  
Nasrin Rahimian ◽  
Soheil Saadat

AbstractThe high prevalence of both Helicobacter.pylori infection and coronary atherosclerosis in our country prompted us to assess the probable association between both conditions. This cross-sectional study recruited 153 patients scheduled to undergo coronary artery angiography. Patients were divided into two groups on the basis of coronary angiography results. Sixty-nine patients had coronary atherosclerosis and the 84 remaining patients were normal. Characteristics and pre-angiographic serum levels of triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein, and Helicobacter.pylori IgG antibody were assessed in the patients and compared between the groups. Helicobacter.pylori infection occurred in 88 (57.51%) patients: 40 (58%) in the atherosclerotic group and 48 (57.1%) in the control group with no significant differences (P=0.918). Our multivariable analysis revealed that Helicobacter.pylori infection was not an independent predictive factor for coronary artery disease (P =0.915). Also, the prevalence of atherosclerosis risk factors with respect to the seropositive and seronegative Helicobacter.pylori infection was assessed in the case group, which showed no significant difference. Furthermore, the prevalence of seropositive Helicobacter.pylori infection in terms of the number of diseased coronary vessels was evaluated, this demonstrated no significant association between the number of the diseased vessels and Helicobacter.pylori infection. This study demonstrated that Helicobacter.pylori infection was not an independent predictive factor of atherosclerosis.


Sign in / Sign up

Export Citation Format

Share Document